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A prospective study of epidemiology and pathogenesis ofcytomegalovirus (CMV)
infections in transplant recipients, previously reported for 30 patients (Clin. Res.
XXII, 441A, 1974), has been extended to include 35 patients who have been studied
clinically and virologically for 5 to 19 months after renal transplantation (RT) (ex-
cept three patients who died within three months after RT). Active CMV infection
was defined as presence of viremia, viruria, and/or a significant rise in the comple-
ment-fixing (CF) antibody titer. Immunosuppression was given since transplantation
and included prednisone, azathioprine or cyclophosphamide, and, in some patients,
antithymocyte globulin. Viremia was detected in 16 (46%) patients (mean onset 2.5
months after RT); viruria in 19 (54%) (mean onset 3.0 months after RT); antibody
rise in 28 (80%) (mean onset 2.8 months after RT); thus 33 (94%) of 35 patients
developed active infection by one or more criteria. One ofthe remaining two patients
had CMV isolated from the lungs at death, one month after RT. Viremia was short-
lived and may have been missed in some patients as sampling was done at monthly in-
tervals. CMV did not infect medical staff personnel under observation during this
study. Only 10% of patients had viruria or CF antibody rise during the hemodialysis
pretransplantation phase of management, and less than 50% of patients received
blood transfusions during the transplant operation. Thus, in most patients CMV in-
fection appears to arise as a result of reactivation of a latent infection. Transfused
blood may be a potential source ofinfection in those patients who received blood dur-
ing orshortly before the surgery.
A distinct clinical syndrome of arthralgias of large joints with or without fever
developed in 21 (60%) ofpatients on the average 2.4 months after RT; in 17 ofthese
its onset was within ± 1 month from the onset ofactive CMV infection. Eight patients
developed, on the average 1.9 months after RT, pulmonary infiltrates which resolved
spontaneously in five patients, whereas in three patients they were associated with
bacterial (staphylococcal and pseudomonas) infection which led to patient's demise.
Mild hepatitis with SGPT levels above 200 Karmen units and serum bilirubin
maximum levels between 2 to 6 mg/100 ml occurred in six patients at a mean interval
of 3.4 months after RT. Twenty-four (69%) patients developed graft rejection (mean
onset 1.2 months after RT) which was irreversible in 14 patients. The first episode of
rejection occurred within + 1 month from the onset ofactive CMV infection in 21 of
the 24 patients with rejection.
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